Vanda Pharmaceuticals Stock Investor Sentiment
| VNDA Stock | USD 4.71 0.25 5.61% |
About 58% of all Vanda Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Vanda Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Vanda Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Vanda Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Vanda |
Vanda Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Vanda Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Vanda Pharmaceuticals that are available to investors today. That information is available publicly through Vanda media outlets and privately through word of mouth or via Vanda internal channels. However, regardless of the origin, that massive amount of Vanda data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Vanda Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Vanda Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Vanda Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Vanda Pharmaceuticals alpha.
Vanda Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Disposition of 8000 shares by Timothy Williams of Vanda Pharmaceuticals at 7.0087 subject to Rule 16b-3 | 11/27/2024 |
2 | Vanda Pharmaceuticals Earns Hold Rating from Analysts at StockNews.com - MarketBeat | 12/10/2024 |
3 | Vanda granted hearing to discuss FDA rejection of application for tradipitant - Seeking Alpha | 01/27/2025 |
4 | Vanda Pharmaceuticals Buy Rating Reaffirmed at HC Wainwright - MarketBeat | 01/28/2025 |
5 | Disposition of 412 shares by Kevin Moran of Vanda Pharmaceuticals at 6.3 subject to Rule 16b-3 | 01/30/2025 |
6 | Vanda Pharmaceuticals and Anaptys sign license agreement for imsidolimab | 02/03/2025 |
7 | Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 | 02/05/2025 |
8 | Vanda Pharmaceuticals GAAP EPS of -0.08 beats by 0.06, revenue of 53.19M beats by 0.94M | 02/13/2025 |
9 | Vanda Pharmaceuticals Inc Q4 2024 Earnings Call Highlights Revenue Growth Amidst Challenges | 02/14/2025 |
10 | Acquisition by Kevin Moran of 2000 shares of Vanda Pharmaceuticals at 4.3894 subject to Rule 16b-3 | 02/21/2025 |
11 | Acquisition by Polymeropoulos Mihael Hristos of 10000 shares of Vanda Pharmaceuticals at 4.464 subject to Rule 16b-3 | 02/25/2025 |
Complementary Tools for Vanda Stock analysis
When running Vanda Pharmaceuticals' price analysis, check to measure Vanda Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vanda Pharmaceuticals is operating at the current time. Most of Vanda Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vanda Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vanda Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vanda Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stocks Directory Find actively traded stocks across global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges |